---
title: "Pharmacokinetics/Pharmacodynamics (PK/PD) of Antimicrobials and Novel Agents"
subtitle: "A workshop for graduate students, pharmacy students, and postdocs"
format: 
  clean-revealjs:
    output-file: index.html
    self-contained: false
html-math-method:
  method: mathjax
  url: "https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"
author:
  - name: Jacob K. McPherson
    orcid: 0000-0001-5486-4945
    email: jacob@jacobkmcpherson.com
    affiliations: University of Houston College of Pharmacy
date: last-modified
---

# Welcome to the Workshop!

## *This workshop was inspired by a conversation that emphasized PK/PD to clinical outcomes (PK/PD/CO)*

<!-- this is a comment in the Quarto document, hidden from render -->

::: {style="text-align: center;"}
<iframe 
    src="https://www.youtube.com/embed/3z4BItBrzbk?si=WMiGwvZnvsreN57v"
    width="800" 
    height="450" 
    style="max-width: 80vw; aspect-ratio: 16/9; border: none;"
    allowfullscreen> </iframe>
:::

## Learning Objectives

-   Describe the fundamental concepts of pharmacokinetics and pharmacodynamics (PK/PD).\
-   Discuss the design and utility of PK/PD studies, including hands-on applications using R programming.
-   translate clinical PK/PD to dose optimization using R programming.
-   Identify PK/PD considerations for new drug development.

## Learning Resources

-   [Workshop agenda (README.md)](https://github.com/JacobKMcPherson/workshop_pkpd_antimicrobials/blob/main/README.md#agenda-overview)\
-   [Scholars program](https://www.gulfcoastconsortia.org/home/research/antimicrobial-resistance/amr-scholars-program/)\
-   [NIAID 2017 Workshop](https://amr.solutions/wp-content/uploads/99/niaid_june2017_pkpdworkshopsummary.pdf)
-   [SIDP 2025 Workshop](https://sidp.org/PKPD)
-   [ESCMID 2026 Workshop](https://www.escmid.org/event-detail/optimised-dosing-of-antibiotics-understanding-pkpd-clinical-breakpoints-and-therapeutic-drug-monitoring-2026/)

# Background Clinical Microbiology


## Bacteriostatic vs. Bactericidal Activity
### Minimum Inhibitory Concentrations (MIC)<sup><a href="https://doi.org/10.1016/j.xpro.2023.102512">1</a></sup>

![](content/images/Barnes2023StarProtocols_mic.jpg){fig-align="center" width="60%"}

---

## Bacteriostatic vs. Bactericidal Activity

### Minimum Bactericidal Concentrations (MBC)<sup><a href="https://doi.org/10.1016/B978-0-12-801238-3.00244-0">2</a></sup>

![](content/images/Bury-Mone2014_mbc_mic_ratio.jpg){fig-align="center" height="90%"}


---


## in vitro Hollow-Fiber Models (HFM)

### subtitle

Content

---

## Pre-clinical Animal Models of Infection

### subtitle

Content

---

## Clinical Drug Therapy Monitoring (DTM)

### subtitle

Content

# Group-Specific Assignment of (6) Clinical Cases

Content

## Group-Specific Assignment of (6) Clinical Cases

### subtitle

Content

# Patient Presentations and Suggestions for Dose-Optimization

Content

## Patient Presentations and Suggestions for Dose-Optimization

### subtitle

Content
